Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06510816 · ClinicalTrials.gov registry record · Phase 3

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)

A Phase 3 study of Geographic Atrophy, sponsored by Annexon.

Active
Registry status
Phase 3
Development phase
659
Enrollment target
20
Study locations

NCT06510816 is a Phase 3 study of Geographic Atrophy that is active but no longer recruiting, run by Annexon. The registered enrollment target is 659 participants, above the 198-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (233% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06510816, a Phase 3 study of Geographic Atrophy, is active but no longer recruiting, sponsored by Annexon.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
659 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).

Conditions Studied

Geographic Atrophy

Interventions

  • OTHER Sham Administration
  • DRUG Vonaprument

Study Locations (20)

California

  • Retina-Vitreous Associates Medical Group - Beverly Hills
  • RCOC Clinical Research Institute Inc - Fullerton
  • Global Research Management - Glendale
  • Retina Consultants Medical Group - Modesto
  • Northern California Retina Vitreous Associates Medical Group, Inc. - Mountain View
  • Retinal Consultants Medical Group - Sacramento
  • Macula Retina Vitreous Research Institute - Torrance
  • Bay Area Retina Associates - Walnut Creek

Florida

  • Rand Eye Institute - Deerfield Beach
  • National Ophthalmic Research Institute - Fort Myers
  • Florida Retina Institute - Orlando
  • Fort Lauderdale Eye Institute - Plantation
  • Retina Group of Florida - Sarasota
  • Retina Vitreous Associates of Florida - St. Petersburg
  • East Florida Eye Institute - Stuart

Colorado

  • Retina Consultants of Southern Colorado PC - Colorado Springs
  • RSC Research, LLC - Denver

Arizona

  • Retina Macula Institute of Arizona - Scottsdale

Georgia

  • Georgia Retina PC - Marietta

Hawaii

  • Retina Consultants of Hawaii - ‘Aiea

Trial Details

FieldValue
Enrollment Target 659 participants
Start Date 2024-07-30
Est. Completion 2027-10-31
Phase Phase 3

Sponsor

Annexon

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06510816

The ClinicalTrials.gov registry entry for NCT06510816 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 659 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 198-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (233% higher). The listed sponsor is Annexon, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Sham Administration is the first listed.

NCT06510816 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT06510816 about?

NCT06510816 is a clinical study titled "A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)". The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).

What is the current status of trial NCT06510816?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 659 participants. The study started on 2024-07-30. Estimated completion is 2027-10-31.

What conditions does trial NCT06510816 study?

This clinical trial studies the following conditions: Geographic Atrophy.

What interventions are being tested in trial NCT06510816?

The interventions under investigation include: Sham Administration (OTHER), Vonaprument (DRUG).

Who is sponsoring clinical trial NCT06510816?

This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06510816 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Geographic Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Geographic Atrophy

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.